Author:
Ankrum James A.,Dastidar Riddhi G.,Ong Joon Faii,Levy Oren,Karp Jeffrey M.
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Ankrum, J. & Karp, J. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 16, 203–209 (2010).
2. Bahr von, L. et al. Long-term complications, immunologic effects and role of passage for outcome in mesenchymal stromal cell therapy. Biol. Blood Marrow Transplant. 18, 557–564 (2012).
3. Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579–1586 (2008).
4. Mills, C. R. Osiris Therapeutics Announces Preliminary Results for PRochymal Phase III GvHD Trials. Osiris Press Release (2009)at <
http://files.shareholder.com/downloads/OSIR/2468414599x0x317779/7677da46-286a-47c4-865d-36c148119a1a/OSIR_News_2009_9_8_General.pdf
>.
5. Galipeau, J. The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 15, 2–8 (2013).
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献